MBA MD - Cullinan Oncology Chief Officer

CGEM Stock  USD 12.54  0.32  2.62%   

Insider

MBA MD is Chief Officer of Cullinan Oncology LLC
Age 51
Phone617 410 4650
Webhttps://cullinantherapeutics.com

Cullinan Oncology Management Efficiency

The company has return on total asset (ROA) of (0.204) % which means that it has lost $0.204 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2653) %, meaning that it created substantial loss on money invested by shareholders. Cullinan Oncology's management efficiency ratios could be used to measure how well Cullinan Oncology manages its routine affairs as well as how well it operates its assets and liabilities.
Cullinan Oncology LLC currently holds 3.59 M in liabilities with Debt to Equity (D/E) ratio of 0.0, which may suggest the company is not taking enough advantage from borrowing. Cullinan Oncology LLC has a current ratio of 9.84, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Cullinan Oncology's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Richard MDLyell Immunopharma
72
Edgar MDBolt Biotherapeutics
78
Brent RiceAutolus Therapeutics
58
Kelly SchickC4 Therapeutics
44
Gregory RussottiCentury Therapeutics
57
Alan RussellEdgewise Therapeutics
54
Dr RobertsLyra Therapeutics
56
Donald MBALyra Therapeutics
70
Kristina ZambourasC4 Therapeutics
N/A
Filip MDMonte Rosa Therapeutics
50
Aya JakobovitsAdicet Bio
69
Adam LevyZentalis Pharmaceuticals Llc
N/A
Pharm PharmDVor Biopharma
76
DPHIL MDVor Biopharma
51
Luis BorgesCentury Therapeutics
62
Bernard JDSana Biotechnology
69
Nathanael GrayC4 Therapeutics
N/A
Sunil MDSana Biotechnology
54
Shane WilliamsCentury Therapeutics
N/A
Silvia BuonamiciMonte Rosa Therapeutics
N/A
ACA BEconAutolus Therapeutics
60
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts. Cullinan Management operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 31 people. Cullinan Oncology LLC (CGEM) is traded on NASDAQ Exchange in USA. It is located in One Main Street, Cambridge, MA, United States, 02142 and employs 85 people. Cullinan Oncology is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Cullinan Oncology LLC Leadership Team

Elected by the shareholders, the Cullinan Oncology's board of directors comprises two types of representatives: Cullinan Oncology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cullinan. The board's role is to monitor Cullinan Oncology's management team and ensure that shareholders' interests are well served. Cullinan Oncology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cullinan Oncology's outside directors are responsible for providing unbiased perspectives on the board's policies.
Jennifer Michaelson, Chief Officer
Kerry Whalen, Director Devel
Jeffrey Trigilio, CFO Treasurer
Mary Fenton, Chief Officer
Jacquelyn JD, Chief Officer
MBA MD, Chief Officer
Patrick Baeuerle, Chief CoFounder
Steve Andre, Chief Officer
Kevin Johnston, Chief Officer
Corinne Savill, Chief Officer
Mary CPA, Chief Officer
Nadim Ahmed, CEO President
Rose Weldon, Senior Communications

Cullinan Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cullinan Oncology a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Cullinan Oncology LLC is a strong investment it is important to analyze Cullinan Oncology's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cullinan Oncology's future performance. For an informed investment choice regarding Cullinan Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cullinan Oncology LLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.
You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cullinan Oncology. If investors know Cullinan will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cullinan Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Cullinan Oncology LLC is measured differently than its book value, which is the value of Cullinan that is recorded on the company's balance sheet. Investors also form their own opinion of Cullinan Oncology's value that differs from its market value or its book value, called intrinsic value, which is Cullinan Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cullinan Oncology's market value can be influenced by many factors that don't directly affect Cullinan Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cullinan Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cullinan Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cullinan Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.